MA-ROCKET-SOFTWARE
5.10.2021 15:02:11 CEST | Business Wire | Press release
Rocket Software , a global technology leader that develops enterprise software used by the world’s largest public and private sector companies, today named Milan Shetti the company’s next CEO, effective November 5. Milan will also retain his President title. Current CEO and co-founder Andy Youniss will become Executive Chairman, providing strategic insights and guidance to Rocket® in important areas where he has experience and expertise. Andy will also remain on Rocket’s Board of Directors.
“From Rocket’s creation almost 32 years ago, we set out to build a long-lasting software company that would make a difference in the world,” Youniss said. “I am incredibly proud of the company we have built, our 2,500 Rocketeers, the culture we embody, and the core values we live every day. This leadership transition is deeply important to me, and we have been intentional and thoughtful in every step of the process.”
Shetti joined Rocket in 2020 as Business Unit President and was named Rocket President earlier this year, overseeing all products in the company’s portfolio. Most recently, he held senior executive positions at Hewlett Packard Enterprise (HPE), including serving as Senior Vice President and General Manager of the multi-billion dollar storage business unit and previously as Chief Technology Officer of the Datacenter Infrastructure and Storage divisions.
“Milan is the right leader for this moment in Rocket’s history and for its future,” Youniss continued. “I have the utmost confidence that under his leadership, Rocket will continue to put our customers and partners first, deliver innovation and quality that matters, and enable even more legendary outcomes."
“I was captivated by how Rocket’s culture and technology strengthen each other,” said Shetti. “The connection Andy created between Rocket’s core values and the way we serve our customers and partners is what excites me most about leading Rocket in this next era, as we continue to accelerate the modernization of mission-critical systems and solve our customers’ and partners’ most pressing, highly technical challenges.”
“Andy has done a remarkable job building Rocket Software into a global technology leader, thoughtfully guiding the company’s growth and success. We are delighted to be able to continue working with him at the board level,” said David Humphrey, a Managing Director at Bain Capital Private Equity and a member of Rocket’s Board of Directors.
“Milan is an established technology leader with deep background in infrastructure management solutions. We are confident his skills and experience will enable Rocket to continue to advance its mission-critical portfolio of enterprise software solutions while furthering the commitment to its customers, employees and business partners,” added Max de Groen, a Managing Director at Bain Capital Private Equity and a member of Rocket’s Board of Directors.
Shetti began his career at Sun Microsystems as a software developer and advanced through a technical career path to technical director for the company’s data management group. After Sun Microsystems, Shetti led business development for IBRIX, Inc. before assuming the chief executive position. He holds a PhD in computer science from the University of Minnesota and a Master of Science in computer engineering from Syracuse University.
About Rocket Software
Rocket Software empowers organizations to create legendary impact in the world through innovation in legacy technologies. With deep expertise in IBM Z®, IBM Power®, and database and connectivity solutions, Rocket provides solutions that power tens of thousands of global businesses, solving real problems and making real-world impact. Rocket is a privately held U.S. corporation headquartered in the Boston area with centers of excellence strategically located throughout North America, Europe, Asia, and Australia. Rocket is a portfolio company of Bain Capital Private Equity.
Legacy Powers Legendary™
© 2021 Rocket Software, Inc. or its affiliates. All Rights Reserved.
Rocket® is a trademark of Rocket Software, Inc. and its subsidiaries, registered in the United States and other jurisdictions worldwide. All other trademarks cited herein are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005323/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 08:00:00 CEST | Press release
€50 million financing package from funds and accounts managed by BlackRock will support IQM to scale operations, accelerate product development, and strengthen its market position. The facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing as IQM prepares for public listing. IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom